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ABSTRACT Diagnosis of primary ciliary dyskinesia (PCD) lacks a “gold standard” test and is therefore
based on combinations of tests including nasal nitric oxide (nNO), high-speed video microscopy analysis
(HSVMA), genotyping and transmission electron microscopy (TEM). There are few published data on the
accuracy of this approach.
Using prospectively collected data from 654 consecutive patients referred for PCD diagnostics we calculated
sensitivity and specificity for individual and combination testing strategies. Not all patients underwent all tests.
HSVMA had excellent sensitivity and specificity (100% and 93%, respectively). TEM was 100% specific, but
21% of PCD patients had normal ultrastructure. nNO (30 nL·min−1 cut-off) had good sensitivity and
specificity (91% and 96%, respectively). Simultaneous testing using HSVMA and TEM was 100% sensitive and
92% specific.
In conclusion, combination testing was found to be a highly accurate approach for diagnosing PCD. HSVMA
alone has excellent accuracy, but requires significant expertise, and repeated sampling or cell culture is often
needed. TEM alone is specific but misses 21% of cases. nNO (⩽30 nL·min−1) contributes well to the diagnostic
process. In isolation nNO screening at this cut-off would miss ∼10% of cases, but in combination with HSVMA
could reduce unnecessary further testing. Standardisation of testing between centres is a future priority.
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Introduction
Recent advances in the diagnosis of patients with primary ciliary dyskinesia (PCD) have included
networks of specialists developing protocol-driven testing [1–4], international consensus guidelines [5] and
rapid expansion of known PCD-related genes [3].
There is no “gold-standard” test for PCD, hence European consensus guidelines (2009) [5] recommend a
combination of tests including nasal nitric oxide (nNO) screening [4, 6], high-speed video microscopy
analysis (HSVMA) of ciliary beat frequency (CBF) and pattern (CBP) [7–10] and transmission electron
microscopy (TEM) analysis of ciliary ultrastructure [11, 12]. Reanalysis following submerged [13] or air–
liquid interface (ALI) [14] culture may be useful to exclude secondary ciliary dyskinesia or confirm PCD
when analysis of the primary sample is abnormal, and may provide additional cilia if the primary sample
is inadequate. The 2009 guidelines [5] also suggest potential adjuncts to diagnosis including
immunofluorescence labelling of cilia proteins [15], pulmonary radioaerosol mucociliary clearance [16, 17]
and genotyping. Since 2009 there have been rapid advances in the discovery of genes responsible for PCD
[1, 3], thus allowing genetic testing to take a prominent position in some countries, but it is currently not
funded in the English public healthcare system. The English PCD service [1, 18] diagnoses PCD using
nNO, HSVMA and TEM, with reanalysis following ALI culture for inconclusive and positive samples.
Several articles have reported the accuracy of individual tests for the diagnosis of PCD, but none have
considered all available diagnostic data. Most reports have failed to include the significant numbers of
“inconclusive” results [19]. The aim of this study was to determine the accuracy of PCD diagnostic tests
(nNO, HSVMA and TEM) when used singularly or in combination, based on a large prospective study
of consecutive patients referred for diagnostic testing.
Methods
Local and national research and development and ethical approvals were obtained (Southampton and
South West Hampshire research ethics 07/Q1702/109).
Participants
868 consecutive subjects were referred to the national PCD centre at University Hospital Southampton
(UHS) for diagnostic testing between 2007 and 2013; 654 had adequate data and samples for inclusion.
The population served by the centre is predominantly Caucasian and nonconsanguineous. Patients
attended UHS or samples were couriered to UHS from satellite referral centres, with no prescreening
of nNO.
Diagnostic testing
The pathway leading to diagnostic outcomes is summarised in figure 1. Details of the method are provided
in the online supplementary material.
Patients and samples
Patients were required to have been free of infection for ⩾4 weeks. At UHS, demographic and clinical
history was recorded using a standard form. At UHS nNO was measured [20] using a chemiluminescence
analyser (NIOX Flex; Aerocrine, Solna, Sweden) aspirating nasal air from the nostril at 0.3 L·min−1 during
a breath-hold manoeuvre. Based on experience, since 2007 we have considered an arbitrary cut-off of
⩽30 nL·min−1. Following nNO measurement, a nasal brush biopsy provided epithelial cells for HSVMA,
TEM and ALI culture.
Satellite centres completed patient proformas and brush biopsies were couriered to UHS. Cells for
HSVMA and ALI culture were transported in buffered medium within 3 h, while fixed samples for TEM
were accepted with longer transportation times.
Laboratory analyses
HSVMA and TEM were analysed in blinded fashion by PCD-specialist microscopists (online
supplementary material). At least six healthy strips of ciliated epithelium were recorded at 500 frames per
second (fps). Sequences were played back at 30 fps to observe the CBP and calculate CBF. CBP was
qualitatively assessed as normal, dyskinetic (static, uncoordinated, rotational, reduced beat amplitude, slow
or hyperfrequent), valid-inconclusive despite adequate sample or invalid-inconclusive due to inadequate
sample. HSVMA was only reported normal if both CBF (normal range 11–20 Hz) and CBP were normal.
TEM analysis was carried out if HSVMA was abnormal or inconclusive. ⩾100 cilia were imaged in transverse
section at ×60000 magnification for the assessment of axonemal structure. Using in-house normative data,
quantitative analysis determined ciliary ultrastructure as normal, abnormal, valid-inconclusive or
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inadequate-inconclusive. HSVMA and/or TEM were reanalysed following ALI culture or repeat biopsy
unless results were normal.
Diagnostic decisions
Data were reviewed at multidisciplinary team meetings, attended by a clinician, an HSVMA microscopist
and a TEM microscopist. All clinical and diagnostic data were considered when agreeing the diagnostic
outcome as PCD-positive, PCD-negative or inconclusive.
Positive diagnosis was reported in patients with typical clinical history, usually with at least two abnormal
diagnostic tests (TEM, HSVMA and nNO), but in patients with a strong history (e.g. sibling with PCD or
“full” clinical phenotype (e.g. neonatal respiratory distress at term followed by daily wet cough, persistent
rhinitis and glue ear, often associated with episodes of upper and lower respiratory tract infection)), we
occasionally reported a positive diagnosis based on “hallmark” TEM or repeated HSVMA consistent with
PCD. CBP was considered positive if the pattern was typical of PCD rather than secondary ciliary
dyskinesia, determined either from two brushing biopsies or from one brushing biopsy with reanalysis
following ALI culture.
Negative diagnosis was reported if 1) HSVMA with or without TEM was normal or 2) HSVMA and
TEM abnormalities were consistent with secondary rather than primary dyskinesia and normal nNO
(if available).
A valid-inconclusive diagnosis was reported if, on repeated testing, adequate samples had subtle
abnormalities not “classical” for PCD but outside the range of our experience of secondary defects. It was
considered that these patients might have subtle or rare variants of ciliary phenotype. Patients were
therefore told that the diagnosis was equivocal, with the recommendation that they received appropriate
treatment (e.g. airway clearance or treatment of exacerbations). They were investigated for other causes of
their symptoms (e.g. cystic fibrosis genotype and immunology) and were kept under review for further
testing as new tests become available (e.g. new PCD-associated mutations).
Clinical history
Normal
"Hallmark" defect
UHS patient age <5 years 
or sample sent by courier
UHS patient
age ≥5 years
Abnormal or
equivocal
Normal or
equivocal
Equivocal
Abnormal or
equivocal
Normal
Abnormal
and/or
"hallmark"
defect
Normal
PCD
negative
PCD
positive
TEM
Cilia ultrastructure
Inconclusive
Further follow-up
PCD
positive
PCD
negative
Repeat HSVMA
and/or TEM
HSVMAnNO andHSVMA
PCD
negative
FIGURE 1 Primary ciliary dyskinesia (PCD) diagnostic pathway for patients and samples. Diagnostic tests
included nasal nitric oxide (nNO), high-speed video microscopy analysis (HSVMA) and transmission electron
microscopy (TEM). Not all patients underwent all tests. UHS: University Hospital Southampton.
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If TEM and HSVMA were inconclusive due to inadequate samples, e.g. sparse cilia, the diagnostic outcome
was invalid-inconclusive and patients were invited for repeat testing. Patients with normal TEM in isolation
were considered invalid-inconclusive, since TEM misses 20–30% of PCD cases [21]. Patients with nNO
⩽30 nL·min−1 were deemed likely to have PCD, but it was never accepted as a lone diagnostic test.
Statistical analysis
Data were prospectively recorded in an Access database (Microsoft, Redmond, WA, USA) and exported to
SPSS Statistics 21 (IBM Corp., Armonk, NY, USA) and GraphPad Prism 6 (La Jolla, CA, USA) for
analysis. Additional details are listed in the online supplementary material.
The distribution of clinical data were examined by univariate analysis. Prevalence of categorical variables
was presented as percentages, and Chi-squared and Fisher’s exact tests assessed proportional differences.
For continuous variables mean±SD with two-tailed parametric (t) or nonparametric (×2, Mann–Whitney)
tests were presented. p<0.05 was considered statistically significant.
For repeated sampling, the most recent test result was used, although all data were considered by the
multidisciplinary team when deciding final diagnostic outcome (figure 1). Patients with inadequate-
inconclusive outcomes were excluded for analysis of test accuracy. The sensitivity and specificity of the
individual tests were determined firstly based on definite positive or negative diagnostic outcome, and then
assuming all valid-inconclusive outcomes to be truly positive or negative (using multidisciplinary diagnosis as a
reference standard). Receiver operating characteristic (ROC) curves were constructed for nNO and CBF. Further
accuracy analysis was completed using HSVMA and TEM as the reference standards.
Additionally, sensitivity, specificity and predictive values were calculated for those who underwent all
diagnostic tests (n=180) and compared with the whole study population (using multidisciplinary diagnosis
as a reference standard); the whole population was then further stratified into: 1) the full protocol at UHS
or 2) partial protocol when samples were couriered to UHS (nNO measurements not taken). We also
allowed for the fact that those aged <5 years did not have nNO readings measured.
For those who underwent all three tests (n=180), theoretical combination testing approaches [22] were
used to determine net sensitivity and specificity of simultaneous (two or more tests in parallel; positive
result if any test was abnormal) and sequential (second test only performed if first test(s) abnormal)
diagnostic protocols. Net sensitivity/specificity used the addition rule of probability for simultaneous tests
and the multiplication rule of probability for sequential tests.
Results
Study population
We assessed 868 patients between April 2007 and December 2013 (48% male; median (range) age
7 (0–79) years). 517 (60%) attended the UHS clinic in person (figure 2a) and 351 samples were delivered
by courier (figure 2b). 75 (9%) patients had a positive diagnosis, 566 (65%) had a negative diagnosis and
13 (1%) had inconclusive diagnostic outcome despite adequate samples. 214 (25%) patients had
invalid-inconclusive results due to inadequate data at the time of the study, of whom 113 (13%) patients
had only TEM samples sent from satellite clinics. Invalid-inconclusive outcomes were excluded from the
analyses, resulting in a study population of 654, of which 641 had a definitive positive or negative
outcome. The characteristics of the positive, negative and inconclusive patients are shown in table 1.
Accuracy of individual diagnostic tests
Analysis was dependent on the quality of the sample and many patients required repeat biopsies: 17%
(113 out of 654) required one repeat; 2% (11 out of 654) required two repeats; and 0.4% (three out of 654)
required three repeats. Analysis of diagnostic accuracy was based on the final successful test completed.
Nasal nitric oxide
nNO was measured in 301 (47%) patients with a positive or negative diagnosis. nNO was significantly
lower in PCD-positive patients (17±20 nL·min−1, 95% CI 10–23 nL·min−1) than negative patients (172±94
nL·min−1, 95% CI 160–183 nL·min−1) (p<0.0001) (online supplementary figure S1). ROC curve analysis
showed low nNO to be a strong predictor of a multidisciplinary diagnosis of PCD (area under the curve
0.97, 95% CI 0.94–1.00) (figure 3). A cut-off of 30 nL·min−1 was sensitive (0.91, 95% CI 0.76–0.98) and
specific (0.96, 95% CI 0.93–0.98) (table 2). Inclusion of eight valid-inconclusive results as PCD-positive
(109.7±119 nL·min−1, 95% CI 10–209 nL·min−1) reduced sensitivity to 0.78 (95% CI 0.62–0.89) (online
supplementary table S1).
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High-speed video microscopy analysis
HSVMA was performed in 625 (98%) patients including 60 PCD-positive and 565 PCD-negative cases.
HSVMA was abnormal in all 60 positive patients tested. Of 565 PCD-negative patients, 39 had abnormal
or equivocal HSVMA results (17 had abnormal CBF and 22 had abnormalities of CBP). HSVMA had
excellent sensitivity (1.00, 95% CI 0.94–1.00) and specificity (0.93, 95% CI 0.91–0.95) (table 2). Since our
definition of PCD includes abnormal ciliary function (pattern or frequency), sensitivity would be expected
to approach 1.00. Inclusion of valid-inconclusive results as PCD-positive kept sensitivity high at 0.97 (95%
CI 0.90–1.00) (online supplementary table S1).
Subgroup analysis (e.g. UHS versus courier-delivered or age <5 years) made little difference to the sensitivity,
specificity or predictive values (tables 2 and 3).
The mean CBF for PCD-positive patients (2.3±5.2 Hz, 95% CI 0.4–4.3 Hz) was significantly lower than for
PCD-negative patients (15.4±2.3 Hz, 95% CI 15.2–15.6 Hz) (p<0.0001) (online supplementary figure S2).
ROC curve analysis showed CBF to discriminate well between PCD-positive and -negative patients (AUC
0.92, 95% CI 0.79–1.00) (figure 3). However, it was not possible to derive a reliable CBF for 31 (41%)
PCD-positive patients with variable CBP.
a)
b)
Patients at
centre
n=517
PCD negative
n=80
PCD positive
n=2
VI
n=5
PCD negative
n=118
PCD negative
n=149
PCD positive
n=33
PCD negative
n=89
PCD positive
n=8
PCD positive
n=1
VI
n=8
HSVMA
n=195
TEM
n=105
nNO + HSVMA
n=322
II
n=10
II
n=3
II
n=21
II
n=8
II
n=3
TEM
n=193
HSVMA
n=181
II (missing data)
n=9
Samples 
received by
courier
n=351
PCD negative
n=59
PCD negative
n=71
PCD positive
n=17
II
n=13
TEM
n=89
II
n=113
PCD positive
n=14
II
n=34
TEM
n=161
FIGURE 2 The diagnostic investigations and outcomes of patients seen a) at the diagnostic centre at University
Hospital Southampton (UHS) or b) having had samples sent by courier to UHS from a satellite respiratory
clinic. Patients were diagnosed as primary ciliary dyskinesia (PCD)-positive, PCD-negative or
valid-inconclusive (VI). Invalid-inconclusive (II) results due to inadequate samples or data are shown, but were
subsequently excluded from accuracy analyses. Diagnostic tests included nasal nitric oxide (nNO), high-speed
video microscopy analysis (HSVMA) and transmission electron microscopy (TEM).
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TABLE 1 Clinical characteristics of the referral population grouped by positive, negative, valid-inconclusive and invalid-inconclusive diagnostic outcomes
Total referrals Positive Negative Valid-inconclusive Invalid-inconclusive
Yes No NA# Yes No NA# Yes No NA# Yes No NA# Yes No NA#
Subjects 868 75 566 13 214
Male 362 (42) 393 (45) 11 (13) 34 (45) 36 (48) 5 (7) 249 (44) 278 (49) 39 (7) 7 (54) 6 (46) 0 (0) 72 (34) 73 (34) 69 (32)
Full-term gestation 346 (40) 102 (12) 420 (48) 66 (88) 7 (9) 2 (3) 242 (43) 80 (14) 244 (43) 8 (61) 2 (15) 3 (23) 30 (14) 13 (6) 171 (80)
Sibling with PCD 32 (4) 792 (91) 44 (5) 18 (24) 55 (73) 2 (3) 9 (2) 529 (93) 28 (5) 0 (0) 11 (85) 2 (15) 5 (2) 197 (92) 12 (6)
Neonatal unit 138 (16) 694 (80) 35 (4) 46 (61) 25 (33) 4 (5) 77 (14) 466 (82) 23 (4) 3 (23) 9 (69) 1 (8) 12 (6) 194 (91) 8 (4)
Situs abnormality 70 (8) 788 (91) 10 (1) 33 (44) 42 (56) 0 (0) 22 (5) 537 (95) 7 (0) 4 (31) 9 (69) 0 (0) 11 (5) 200 (93) 3 (1)
Cardiac abnormality 20 (2) 848 (98) 0 (0) 6 (8) 69 (92) 0 (0) 10 (2) 556 (98) 0 (0) 0 (0) 13 (100) 0 (0) 4 (2) 210 (98) 0 (0)
Pulmonary symptoms 710 (82) 158 (18) 0 (0) 72 (96) 3 (4) 0 (0) 488 (86) 78 (14) 0 (0) 12 (93) 1 (7) 0 (0) 138 (64) 76 (36) 0 (0)
Rhinitis 477 (55) 389 (45) 2 (0) 61 (81) 14 (19) 0 (0) 325 (57) 239 (42) 2 (1) 9 (69) 4 (31) 0 (0) 82 (38) 132 (62) 0 (0)
Sinusitis 192 (22) 663 (76) 13 (2) 21 (28) 53 (71) 1 (1) 138 (24) 416 (74) 12 (2) 5 (38) 8 (62) 0 (0) 28 (13) 186 (87) 0 (0)
Data are presented as n or n (%). Patients with invalid-inconclusive outcomes were excluded from the study population for analyses. NA: not available; PCD: primary ciliary dyskinesia.
#: for example, children did not know their fertility status; older adults did not know neonatal details; and in a minority of cases the data were simply not recorded.
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Transmission electron microscopy
TEM was performed on samples from 368 (57%) patients including 72 PCD-positive and 297 PCD-negative
cases. 57 (79%) out of 72 PCD-positive patients had hallmark ultrastructural defects of PCD: 31% with
outer dynein arm (ODA) and inner dynein arm (IDA) defects; 26% with an ODA defect; 10% with an
ODA defect and suspected IDA defect; 7% with microtubule disarrangement and IDA defect; 4% with an
intermittent central pair microtubule defect; and 1% with a microtubule transposition defect. 21% had
“normal” ciliary ultrastructure. None of the 297 PCD-negative patients had ultrastructural changes
suggestive of PCD, but secondary changes (e.g. swollen membranes or compound cilia) were fairly frequent.
TEM sensitivity was 0.79 (95% CI 0.68–0.88) and specificity was 1.0 (95% CI 0.99–1.00) (table 2). Again,
subgroup analysis made little difference to the sensitivity, specificity or predictive values (tables 2 and 3).
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FIGURE 3 Receiver operating characteristic (ROC) curve analysis for ciliary beat frequency (CBF) and nasal
nitric oxide (nNO) for predicting a diagnosis of primary ciliary dyskinesia (PCD) (using multidisciplinary
diagnosis as the reference standard). ROC curve analysis showed that nNO ⩽30 nL·min−1 (area under the
curve (AUC) 0.97, 95% CI 0.94–1.00) was superior to CBF (AUC 0.92, 95% CI 0.79–1.00) as predictors of a
PCD-positive diagnosis.
TABLE 2 The diagnostic accuracy of nasal nitric oxide (nNO), high-speed video microscopy
analysis (HSVMA) and transmission electron microscopy (TEM) analysis to diagnose primary
ciliary dyskinesia
nNO ⩽30 nL·min−1 HSVMA TEM
Subjects# 301 (47) 625 (98) 368 (57)
Positive patients¶ 34 (45) 60 (80) 71 (95)
Negative patients+ 267 (47) 565 (100) 297 (52)
True positive 31 60 56
True negative 257 526 297
False positive 10 39 0
False negative 3 0 15
Sensitivity (95% CI) 0.91 (0.76–0.98) 1.00 (0.94–1.00) 0.79 (0.68–0.88)
Specificity (95% CI) 0.96 (0.93–0.98) 0.93 (0.91–0.95) 1.00 (0.99–1.00)
PPV (95% CI) 0.76 (0.60–0.88) 0.61 (0.50–0.70) 1.00 (0.94–1.00)
NPV (95% CI) 0.99 (0.97–1.00) 1.00 (0.99–1.00) 0.95 (0.92–0.97)
Data are presented as n (%) or n, unless otherwise stated. Data were analysed for patients with conclusive
positive or negative results who underwent the individual tests. PPV: positive predictive value; NPV: negative
predictive value. #: n=641; ¶: n=75; +: n=566.
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Air–liquid interface culture
ALI culture was performed on 808 samples and 241 (30%) ciliated. Ciliary function was reanalysed
following ALI culture in 152 (24%) patients. ALI samples confirmed a persistent abnormality of CBP in 21
out of 21 PCD-positive patients. Out of 124 PCD-negative patients, 123 had a normal CBP following ALI
culture, and one patient had uncoordinated cilia, perhaps due to variable cell health.
Accuracy of combinations of tests
Various combinations of diagnostic tests are undertaken at our centre (figure 2) while alternative
combinations are used in other centres [23]. We calculated accuracy for the combinations of tests in 180
patients who had undergone all diagnostic tests, allowing us to consider theoretical scenarios (table 4). If
nNO had been used as a screening test followed sequentially by TEM, 36 patients would have proceeded
to TEM, but three out of 31 PCD patients would have been “missed” by not proceeding to further testing
due to false negative nNO results; TEM would have subsequently failed to identify nine PCD patients. The
net specificity for this combination of tests was excellent (100%), but net sensitivity was poor, failing to
identify PCD in 12 (39%) out of 31 patients. Alternatively, if nNO had been used as a screening test
followed sequentially by HSVMA, three out of 31 PCD patients would not have proceeded to HSVMA;
however, HSVMA would have subsequently identified all 28 positive patients. Therefore, the net sensitivity
and specificity were 90% and 100%, respectively.
Excellent net sensitivity and specificity were achieved upon simultaneous testing of HSVMA with nNO
(100% and 87%, respectively) or HSVMA with TEM (100% and 92%, respectively) or all three tests (100%
and 87%, respectively).
Accuracy of individual tests using HSVMA or TEM as the reference standard
We calculated the accuracies of individual tests assuming HSVMA and TEM to be the reference standard
for diagnosing PCD. When TEM analysis was considered as the reference standard, HSVMA sensitivity
and specificity were 1.00 and 0.86, respectively, and nNO (⩽30 nL·min−1) sensitivity and specificity were
0.95 and 0.89, respectively. When HSVMA was considered as the reference standard, TEM sensitivity was
0.48 (95% CI 0.38–0.59) and specificity was 1.00 (95 % CI 0.98–1.00); nNO (⩽30 nL·min−1) sensitivity
was 0.50 and specificity was 0.96 (online supplementary table S2).
Discussion
Our large cross-sectional study provides prospectively collected outcome data following a comprehensive
range of PCD diagnostic tests. Our diagnostic algorithm varies from some centres [23], but the findings
may contribute to the development of international consensus.
A strength of this study was analyses of consecutive referrals within a national diagnostic programme, as
this is likely to yield the most valid estimates of diagnostic accuracy. Although not all patients underwent
all tests, this pragmatic study reflects the real patient journey. The major limitation is the lack of a “gold
reference standard”; we therefore used a surrogate standard of expert multidisciplinary consensus. Since
each test contributes to the final decision, sensitivity and specificity might be overestimated. Additionally,
genetic testing does not currently form part of our diagnostic pathway and this is a rapidly expanding area
that is used for diagnosis in many countries.
11.5% of patients with adequate samples were diagnosed as PCD-positive, which is slightly lower than some
centres [6, 8, 24], but is similar to or higher than others (Switzerland, Amsterdam and London (Claudia
Kuehni, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Eric Haarman,
VU University Medical Center, Amsterdam, the Netherlands; and Claire Hogg, Royal Brompton & Harefield
NHS Foundation Trust, London UK; personal communications). Higher positive rates may be seen at
centres with nNO prescreening, in consanguineous populations [25] or if access to testing is restricted to
those who are extremely likely to have PCD. The prevalence in referral populations will not affect the
sensitivity or specificity but will alter the positive and negative predictive values of the tests.
High-speed video microscopy analysis
HSVMA was sensitive and specific for diagnosing PCD; however, if used as a reference standard, this
would lead to a high number of false positive results. In line with many European centres we consider
HSVMA a first-line test, which might inflate the sensitivity; this needs further investigation in blinded
studies. Since HSVMA is a qualitative test with potential subjectivity, results are regularly validated by
external experts, but this does not exclude the possibility of some false negative findings. PCD-negative
patients all had predominantly normal HSVMA, but often included a proportion of dyskinetic cilia
probably due to recent infection or damage during sampling [26]. Some PCD patients had areas of
844 DOI: 10.1183/13993003.00749-2015
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TABLE 3 The diagnostic accuracy of nasal nitric oxide (nNO), high-speed video microscopy analysis (HSVMA) and transmission electron microscopy (TEM) analysis to
diagnose primary ciliary dyskinesia
UHS Courier
<5 years >5 years <5 years >5 years
HSVMA TEM nNO ⩽30 nL·min−1 HSVMA TEM HSVMA TEM HSVMA TEM
Subjects 126 355 80 80
Total 125 (99) 67 (53) 301 (85) 353 (99) 212 (60) 71 (89) 48 (60) 76 (95) 41 (51)
Positive 8 (6) 7 (10) 34 (11) 34 (10) 33 (16) 8 (11) 17 (35) 10 (13) 14 (34)
Negative 117 (94) 60 (90) 267 (89) 319 (90) 179 (84) 63 (89) 31 (65) 66 (87) 27 (66)
True positive 8 6 31 34 22 8 15 10 13
True negative 111 60 257 297 179 59 31 59 27
False positive 6 0 10 22 0 4 0 7 0
False negative 0 1 3 0 11 0 2 0 1
Sensitivity (95% CI) 1.00 (0.63–1.00) 0.86 (0.42–0.98) 0.91 (0.76–0.98) 1.00 (0.90–1.00) 0.67 (0.48–0.82) 1.00 (0.63–1.00) 0.88 (0.64–0.98) 1.00 (0.69–1.00) 0.93 (0.66–0.99)
Specificity (95% CI) 0.95 (0.89–0.98) 1.00 (0.94–1.00) 0.96 (0.93–0.98) 0.93 (0.90–0.96) 1.00 (0.98–1.00) 0.94 (0.85–0.98) 1.00 (0.89–1.00) 0.89 (0.79–0.96) 1.00 (0.87–1.00)
PPV (95% CI) 0.57 (0.29–0.82) 1.00 (0.54–1.00) 0.76 (0.60–0.88) 0.61 (0.47–0.74) 1.00 (0.84–1.00) 0.67 (0.35–0.90) 1.00 (0.78–1.00) 0.59 (0.33–0.81) 1.00 (0.75–1.00)
NPV (95% CI) 1.00 (0.97–1.00) 0.98 (0.91–1.00) 0.99 (0.97–1.00) 1.00 (0.99–1.00) 0.94 (0.90–0.97) 1.00 (0.94–1.00) 0.94 (0.80–0.99) 1.00 (0.94–1.00) 0.96 (0.82–0.99)
Data are presented as n or n (%), unless otherwise stated. Analyses were stratified by patients seen at University Hospital Southampton (UHS) and samples sent by courier to UHS; then
stratified further by age <5 years and ⩾5 years at time of assessment. PPV: positive predictive value; NPV: negative predictive value.
TABLE 4 Sensitivity and specificity of high-speed video microscopy analysis (HSVMA), ciliary beat pattern, nasal nitric oxide (nNO) and transmission electron
microscopy (TEM) applied as single or combined tests, using simultaneous or sequential testing
Single testing Simultaneous testing Sequential two-stage testing
nNO HSVMA TEM nNO + HSVMA HSVMA + TEM nNO + HSVMA + TEM 1. nNO#
2. HSVMA¶
1. nNO#
2. TEM¶
1. nNO + HSVMA#
2. TEM+
1. HSVMA#
2. TEM§
Subjects 180 180 180 180 180 180 36 36 51 43
Positive 31 31 31 31 31 31 28 28 31 31
Negative 149 149 149 149 149 149 8 8 20 12
True positive 28 31 20 31 31 31 28 19 20 20
True negative 141 137 149 129 137 129 8 8 20 12
False positive 8 12 0 20 12 20 0 0 0 0
False negative 3 0 11 0 0 0 0 9 11 11
Sensitivity (95% CI) 0.90 (0.74–0.98) 1.00 (0.89–1.00) 0.65 (0.45–0.81)
Specificity (95% CI) 0.95 (0.90–0.98) 0.92 (0.86–0.96) 1.00 (0.98–1.00)
PPV (95% CI) 0.78 (0.61–0.90) 0.72 (0.56–0.85) 1.00 (0.83–1.00)
NPV (95% CI) 0.98 (0.94–1.00) 1.00 (0.97–1.00) 0.93 (0.88–0.97)
Net sensitivity ƒ 1.00 1.00 1.00 0.90 0.61 0.65 0.65
Net specificity ƒ 0.87 0.92 0.87 1.00 1.00 1.00 1.00
Data are presented as n, unless otherwise stated. PPV: positive predictive value; NPV: negative predictive value. #: n=180; ¶: n=36; +: n=51; §: n=43; ƒ: the net sensitivity and specificity
were calculated for combined tests.
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apparently normal ciliary function, highlighting that PCD scientists require significant experience of the
qualitative and quantitative range of PCD and non-PCD samples.
HSVMA standardisation is challenging, and robust training, data validation, external audit and continued
learning is in place. Our data cannot be generalised to centres where different standards apply. HSVMA
requires expensive high-speed video equipment, high optical magnification and digital resolution for
accurate CBP analysis, without which errors are likely. CBF is pH and temperature dependent, and we
conduct analyses using pH-stable medium equilibrated to 37°C [27, 28].
Inadequate samples and inconclusive results were a common issue for HSVMA. Recent reports of
PCD-causing genes associated with subtle changes at HSVMA and TEM [29, 30] have confirmed our
suspicion that some inconclusive results might represent disease. Moreover, samples providing inadequate
cilia may be caused by mutations causing a syndrome similar to PCD associated with sparse but normal
cilia [31, 32]. It is possible that some patients excluded from analyses due to inadequate samples will fall
into this category. However, in our experience, inadequate samples are commonly adequate upon repeat
brushing following antibiotics and when patients are well. We always recommend repeat testing for
inadequate samples; some invalid-inconclusive cases did not return for testing because symptoms had
resolved or an alternative diagnosis was identified.
Transmission electron microscopy
Approximately a fifth of PCD patients had apparently normal ciliary ultrastructure, confirming that TEM is
unreliable in isolation [21, 33]. However, it is a vital part of the diagnostic portfolio, supporting HSVMA
findings and providing a diagnosis when HSVMA is not available or inconclusive. Analysis of ciliary
ultrastructure requires expensive equipment and electron microscopists experienced in the range of
normality and abnormality. Some abnormalities are straightforward (e.g. ODA defect), but we have
diagnosed several patients with subtle abnormalities of microtubules, supported by nNO and HSVMA, that
would only be detected by an experienced microscopist analysing sufficient numbers of cilia in transverse
and longitudinal section.
Nasal nitric oxide
nNO is a recommended screening test for symptomatic patients [5, 6, 34]. At the outset of the prospective
data collection in 2007, a cut-off of 30 nL·min−1 was arbitrarily set based on prior experience. Recent
evidence suggests that higher cut-offs may be more useful [4, 34], and the accuracy of nNO cut-offs for
screening/diagnostics needs to be standardised based on emerging evidence. 30 nL·min−1 was used clinically
throughout data collection and so it is on this basis that we have analysed the data. The sensitivity and
specificity of this cut-off were 0.91 and 0.96, respectively. Therefore, 9% of cases might be missed if further
testing was excluded on the basis of this test in isolation. 77 nL·min−1 has recently been recommended as a
cut-off [4]; this cut-off improved sensitivity in our population to 96%, but reduced specificity to 83%. In
LEIGH et al.’s [4] study, sensitivity to detect patients with PCD diagnosed by TEM or genetics was 0.98 while
specificity was >0.75, similar to our findings. In our centre we are confident to use a cut-off of 30 nL·mL−1
because it is always alongside a HSVMA result. In our opinion, if nNO is used by referral centres to decide
who to refer for testing, the higher cut-off with greater sensitivity should be used, but it is notable that 4% of
cases might still be missed. We use nNO to support a positive diagnosis in patients with consistent subtle
abnormalities of CBP who might otherwise be labelled inconclusive. We would be cautious to exclude a
diagnosis of PCD in patients with nNO ⩽30 nL·min−1, and these patients are more likely to be considered
inconclusive and therefore undergo repeated testing. Only 47% of the study population underwent nNO
testing, because it is not available at satellite centres and the breath-hold manoeuvre is usually technically
acceptable only in those aged >5 years. However, the present article reports nNO data from 301 participants,
which constitutes the largest study to date in a PCD diagnostic clinic population.
Accuracy of combinations of tests
Data from patients who had undergone all tests (n=180) were used to calculate the accuracy for possible
combinations of tests. Two-stage testing based on nNO prescreening followed by TEM potentially missed
∼40% of PCD cases, because both tests were required to be positive for a positive diagnosis [22]. However,
our 30 nL·min−1 cut-off is probably too low for use as a screening threshold [34] and the previously
discussed subjectivity of HSVMA needs to be taken into account. Simultaneous testing requires one
positive test result for a positive diagnosis and, conversely, all tests to be negative for a negative outcome
[22]. Using all three tests simultaneously (where any abnormal test leads to a positive result) sensitivity
was 100%, but specificity reduced to 87%, compared to our multidisciplinary approach where no test was
considered in isolation (100% sensitivity and 92% specificity).
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Concluding comments
Advances in understanding the molecular genetic basis of PCD have been made in recent years, to the
extent that genetic testing is now able to detect ∼65% of PCD cases. However, genetic testing for PCD is
not yet available in the UK except as a research tool [1]. As more genes are identified, genetic testing by
multigene panel [1] will make genotyping a cost-effective approach. Characterisation of ciliary structure
and function will continue to have a place within diagnostic processes, similar to the need for functional
tests to confirm the diagnosis of cystic fibrosis [35]. Moreover, a thorough definition of disease phenotype
by cilia ultrastructure, cilia beat pattern and nNO production rate will be extremely helpful in guiding
genetic analyses in this genetically heterogeneous disease. The English public healthcare system does not
fund immunofluorescence staining of ciliary proteins as a diagnostic test. This method is currently only
able to detect abnormalities that are evident by TEM, and would therefore not improve our diagnostic
accuracy. However, we anticipate that as more antibodies become available, immunofluorescence staining
will prove a time- and cost-efficient diagnostic test.
There is no single diagnostic test that can be used universally to diagnose PCD. Recent reports of
PCD-causing genes (RSPH1) associated with subtle HSVMA and TEM abnormalities with normal nNO
demonstrate the skill and expert microscopists needed for accurate diagnoses [29, 30, 36].
Importantly, the conduct and reporting of tests used to diagnose PCD are not standardised. We believe
that the time is right to develop consensus standards for equipment, staff experience and protocols.
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